Subscribe to our Newsletters !!
There is one fact about life on Earth we cannot es
Enter any scientific lab and among the first tools
The Nobel Prize in Physiology or Medicine awarded
Shilpa Medicare – the full-service contract de
Alembic Pharmaceutica
Tofu has been a favorite food for vegetarians and
Dear Readers, Welcome to the latest issue of Micr
French pharmaceutical company Sanofi on Friday announced the launch of human trials of its next COVID-19 vaccine, with its first still in the testing period after having fallen behind in development.
Sanofi and US firm Translate Bio are growing the vaccine based on messenger RNA technology.
The phase 1 and 2 trials aim to confirm that the vaccine is not dangerous and to provide initial information on its effectiveness.
Phase 3 could be carried out on many more patients to find out its effectiveness.
The first trials will include 415 people, with inital results anticipated in the third quarter.
Messenger RNA technology can be used in the Pfizer/BioNTech and Moderna vaccines, already authorised in the European Union, America and elsewhere.
It’s the second vaccine developed by Sanofi against the coronavirus.
An earlier candidate, developed with Britain’s GSK, is recombinant protein-based, but its development is a few months behind schedule and testing is only in stage 2, with hopes to launch it in late 2021.
